COVID-19 clinical trials: who is likely to participate and why?
Journal of Comparative Effectiveness Research · 2024
DOI: 10.57264/cer-2023-0181 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2024. Verfasst von Kimberly A Fisher und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Health Systems Science, Department of Medicine, UMass Chan Medical School, Worcester, MA 01655, USA. Hauptthemen laut MEDLINE: COVID-19, Clinical Trials as Topic. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Aim
To identify factors associated with willingness to participate in a COVID-19 clinical trial and reasons for and against participating. Materials & methods: We surveyed Massachusetts (MA, USA) residents online using the Dynata survey platform and via phone using random digit dialing between October and November 2021. Respondents were asked to imagine they were hospitalized with COVID-19 and invited to participate in a treatment trial. We assessed willingness to participate by asking, “Which way are you leaning” and why. We used multivariate logistic regression to model factors associated with leaning toward participation. Open-ended responses were analyzed using conventional content analysis.
Results
Of 1071 respondents, 65.6% leaned toward participating. Multivariable analyses revealed college-education (OR: 1.59; 95% CI: 1.11, 2.27), trust in the healthcare system (OR: 1.32; 95% CI: 1.10, 1.58) and relying on doctors (OR: 1.77; 95% CI: 1.45, 2.17) and family or friends (OR: 1.31; 95% CI: 1.11, 1.54) to make health decisions were significantly associated with leaning toward participating. Respondents with lower health literacy (OR: 0.57; 95% CI: 0.36, 0.91) and who identify as Black (OR: 0.40; 95% CI: 0.24, 0.68), Hispanic (OR: 0.61; 95% CI: 0.38, 0.98), or republican (OR: 0.61; 95% CI: 0.38, 0.97) were significantly less likely to lean toward participating. Common reasons for participating included helping others, benefitting oneself and deeming the study low risk. Common reasons for leaning against were deeming the study high risk, disliking experimental treatments and not wanting to be a guinea pig.
Conclusion
Our finding that vulnerable individuals and those with lower levels of trust in the healthcare system are less likely to be receptive to participating in a COVID-19 clinical trial highlights that work is needed to achieve a healthcare system that provides confidence to historically disadvantaged groups that their participation in research will benefit their community.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Health Systems Science, Department of Medicine, UMass Chan Medical School, Worcester, MA 01655, USA.
- Division of Pulmonary & Critical Care Medicine, Department of Medicine, UMass Chan Medical School, Worcester, MA 01655, USA.
- Tan Chingfen Graduate School of Nursing, UMass Chan Medical School, Worcester, MA 01655, USA.
- Section of Infectious Diseases, Department of Medicine, Boston Medical Center, Section of Infectious Diseases, Department of Medicine, Boston University School of Medicine, & Boston University School of Public Health, B…
ORCID-Profile: Kimberly A Fisher
Förderung
- NHLBI NIH HHS
Zitieren
APA
Fisher, K. A., Epstein, M. M., Nguyen, N., Fouayzi, H., Crawford, S., Linas, B. P., & Mazor, K. M. (2024). COVID-19 clinical trials: who is likely to participate and why?. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2023-0181
Vancouver
Fisher KA, Epstein MM, Nguyen N, Fouayzi H, Crawford S, Linas BP, et al. COVID-19 clinical trials: who is likely to participate and why?. Journal of Comparative Effectiveness Research. 2024. doi:10.57264/cer-2023-0181
BibTeX
@article{Fisher2024,
author = {Fisher, Kimberly A and Epstein, Mara M and Nguyen, Ngoc and Fouayzi, Hassan and Crawford, Sybil and Linas, Benjamin P and Mazor, Kathleen M},
title = {COVID-19 clinical trials: who is likely to participate and why?},
journal = {Journal of Comparative Effectiveness Research},
year = {2024},
doi = {10.57264/cer-2023-0181}
}
EUVIMED